Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial.
England
Timothy J
TJ
Stroke Trials Unit, Institute of Neuroscience, University of Nottingham, Clinical Sciences Building, City Hospital Campus, Nottingham NG7 2UH, UK.
Bath
Philip M W
PM
Sare
Gillian M
GM
Geeganage
Chamila
C
Moulin
Thierry
T
O'Neill
Desmond
D
Woimant
France
F
Christensen
Hanne
H
De Deyn
Peter
P
Leys
Didier
D
Ringelstein
E Bernd
EB
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000188:drug therapy / Q000473:pathology*; D002544:Cerebral Infarction / Q000188:drug therapy / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology*; D000078222:Tinzaparin; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; D000078222:Tinzaparin; D001241:Aspirin